drugset / Trial / NCT04303377
Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction
Phase 2
Withdrawn
Fondazione IRCCS Policlinico San Matteo di Pavia
Azienda Ospedaliera Ordine Mauriziano di Torino · collabAzienda Ospedaliera San Gerardo di Monza · collabAzienda Ospedaliera Sant'Anna e San Sebastiano · collabAzienda Ospedaliera, Ospedale Civile di Legnano · collabCentro Cardiologico Monzino · collabFondazione Poliambulanza Istituto Ospedaliero · collabOspedale Bassini Cinisello Balsamo · collabOspedale Policlinico San Martino · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI), comparing Evolocumab versus Standard of Care.
Timeline
- Start
- 2019-11-18
- Primary completion
- 2020-01-02
- Completion
- 2020-07-24
Outcome
Outcome not reported
Stopped (Enrollment): “The sponsor required early termination of the economic agreement due to a supposed extension of the enrollment period for bureaucracy reasons and for the concomitant Covid -19 Pandemic”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | 140 mg | — |